Skip to main content
HVIVO PLC logo

HVIVO PLC — Investor Relations & Filings

Ticker · HVO ISIN · GB00B9275X97 LEI · 213800VT5KBM7JLIV118 IL Professional, scientific and technical activities
Open in API
Filings indexed 758 across all filing types
Latest filing 2025-02-27 M&A Activity
Country GB United Kingdom
Listing IL HVO

About HVIVO PLC

https://hvivo.com/

hVIVO plc is a full-service contract research organization (CRO) and a leading specialist in human challenge trials. The company provides end-to-end clinical development solutions for a global biopharma client base, focusing on infectious and respiratory diseases. Its services span from preclinical consultancy to Phase III clinical trials, including first-in-human studies, biometry, and consulting. hVIVO operates a state-of-the-art quarantine facility in London and provides advanced laboratory services under its hLAB brand. Through subsidiaries such as CRS and Venn Life Sciences, it offers early-phase clinical trial expertise and patient recruitment across multiple clinical sites. The company's integrated approach is designed to accelerate the development of vaccines and therapeutics.

Recent filings

Filing Released Lang Actions
Acquisition of Cryostore for up to £3.2m
M&A Activity Classification · 98% confidence The document is a formal announcement released via RNS (RNS Number: 6192Y) on February 27, 2025. The content details a specific corporate action: the acquisition of Cryostore by hVIVO plc for up to £3.2 million. This type of announcement, which details a significant corporate transaction (M&A activity), is typically classified as a Regulatory Filing or a specific M&A announcement. Since there is a specific category for M&A Activity (TAR), this is the most appropriate classification. It is not a full Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). It is a direct announcement of a transaction, not just a notice that a report is attached (RPA).
2025-02-27 English
£2m hMPV characterisation study contract
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 2613X' and contains contact information referencing 'RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This strongly indicates a regulatory news service announcement. The content details a new contract win (£2m hMPV characterisation study contract) and provides business updates, which is typical for a company making a material announcement via the regulatory news service. Since it is a specific business update (contract win) rather than a general regulatory filing, a dividend notice, or a formal report (like 10-K or IR), the most appropriate classification is RNS, which serves as the general regulatory announcement category for material news not covered by more specific codes like DIV or ER. The document length (7555 chars) is substantial enough that it is the announcement itself, not just a brief notice of publication (RPA).
2025-02-17 English
Shionogi reports positive RSV trial results
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 9106V' and concludes with information provided by 'Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange.' This strongly indicates a regulatory announcement distributed via the RNS system. The content itself is a press release detailing positive results from a clinical trial conducted by hVIVO for a client (Shionogi). This type of announcement, which is a general corporate update distributed through a regulatory news service but doesn't fit the specific definitions of 10-K, ER, DIV, or DIRS, is best classified as a general Regulatory Filing (RNS) or potentially a Report Publication Announcement (RPA) if it were announcing the release of a formal report. Since this is the announcement of clinical trial results (a significant corporate event) distributed via RNS, RNS is the most appropriate general category for non-standard regulatory news releases.
2025-02-05 English
RSV contract signed with Inhalon Biopharma
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated '03 February 2025'. It announces a significant business event: 'RSV human challenge trial contract signed with new client, Inhalon Biopharma'. The text explicitly states, 'The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.' The presence of the RNS Number, the reference to RIS (Regulatory Information Service), and the nature of the announcement (a material contract win) strongly indicate this is a regulatory news service announcement. Since it is a general, material announcement that doesn't fit the specific categories like Earnings Release (ER), Director's Dealing (DIRS), or Capital Change (CAP), the most appropriate classification is Regulatory Filings (RNS), which serves as the general regulatory announcement category.
2025-02-03 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled as 'TR-1: Standard form for notification of major holdings' and is distributed via 'RNS Number'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. The content details the shareholder (JPMorgan Asset Management Holdings Inc.), the date the threshold was crossed, and the resulting position in terms of voting rights. This matches the criteria for 'Major Shareholding Notification' (MRQ).
2025-01-31 English
Holding(s) in Company
Director's Dealing Classification · 98% confidence The document is explicitly labeled with "RNS Number : 3660V" and contains the header "TR-1: Standard form for notification of major holdings". This form is used to report changes in major shareholdings, which directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content is a mandatory regulatory disclosure about ownership thresholds being crossed, making MRQ the most precise classification over the general RNS fallback.
2025-01-31 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.